Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer

Eiber, Matthias; Weirich, Gregor; Holzapfel, Konstantin; Souvatzoglou, Michael; Haller, Bernhard; Rauscher, Isabel; Beer, Ambros J.; Wester, Hans‐Juergen; Gschwend, Juergen E.; Schwaiger, Markus; Maurer, Tobias

doi:10.1016/j.eururo.2015.12.053

Cited by 498 publications

(413 citation statements)

References 38 publications

Supporting

Mentioning

367

Contrasting

Unclassified

Order By: Relevance

“…Results from combining 68 Ga-PSMA-11 and multiparametric MRI on 53 preoperative intermediate-/high-risk patients indicated a potential for targeting biopsies. Hybrid 68 Ga-PSMA-11 PET/MRI significantly outperformed multiparametric MRI and 68 Ga-PSMA-11 PET in sensitivity and specificity for tumor localization on a sextant basis (respectively, 76% and 97% for hybrid 68 Ga-PSMA-11 PET/MRI, 58% and 82% for multiparametric MRI, and 64% and 94% for 68 Ga-PSMA PET) (53).…”

Section: Primary Stagingmentioning

confidence: 99%

PSMA Ligands for PET Imaging of Prostate Cancer

et al. 2017

Self Cite

View full text Add to dashboard Cite

Section: Primary Stagingmentioning

confidence: 99%

PSMA Ligands for PET Imaging of Prostate Cancer

et al. 2017

Self Cite

View full text Add to dashboard Cite

“…Radiolabeled ligands targeting PSMA have recently been the subject of numerous studies showing high sensitivity and contrast in detecting recurrent prostate cancer and its metastases with remarkable detection rates (4)(5)(6)(7). Recent studies have also shown a high sensitivity of PSMA-targeted imaging in determining the local extent of disease before radical prostatectomy (8)(9)(10). The high PSMA expression in prostate cancer metastases makes it also a promising approach to develop new tracers for targeted radionuclide therapies.…”

mentioning

confidence: 99%

German Multicenter Study Investigating¹⁷⁷Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients

et al. 2016

View full text Add to dashboard Cite

177 Lu-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy (RLT) of patients with metastatic castrationresistant prostate cancer (mCRPC). Initiated by the German Society of Nuclear Medicine, a retrospective multicenter data analysis was started in 2015 to evaluate efficacy and safety of 177 Lu-PSMA-617 in a large cohort of patients. Methods: One hundred forty-five patients (median age, 73 y; range, 43-88 y) with mCRPC were treated with 177 Lu-PSMA-617 in 12 therapy centers between February 2014 and July 2015 with 1-4 therapy cycles and an activity range of 2-8 GBq per cycle. Toxicity was categorized by the common toxicity criteria for adverse events (version 4.0) on the basis of serial blood tests and the attending physician's report. The primary endpoint for efficacy was biochemical response as defined by a prostate-specific antigen decline $ 50% from baseline to at least 2 wk after the start of RLT. Results: A total of 248 therapy cycles were performed in 145 patients. Data for biochemical response in 99 patients as well as data for physician-reported and laboratory-based toxicity in 145 and 121 patients, respectively, were available. The median follow-up was 16 wk (range, 2-30 wk). Nineteen patients died during the observation period. Grade 3-4 hematotoxicity occurred in 18 patients: 10%, 4%, and 3% of the patients experienced anemia, thrombocytopenia, and leukopenia, respectively. Xerostomia occurred in 8%. The overall biochemical response rate was 45% after all therapy cycles, whereas 40% of patients already responded after a single cycle. Elevated alkaline phosphatase and the presence of visceral metastases were negative predictors and the total number of therapy cycles positive predictors of biochemical response. Conclusion: The present retrospective multicenter study of 177 Lu-PSMA-617 RLT demonstrates favorable safety and high efficacy exceeding those of other third-line systemic therapies in mCRPC patients. Future phase II/III studies are warranted to elucidate the survival benefit of this new therapy in patients with mCRPC.

show abstract

“…This study found 39% sensitivity, 89% specificity, a PPV of 73% and an NPV of 58% and 65% accuracy for MRI versus 17% sensitivity, 96% specificity, 81% PPV, 53% NPV, and 57% accuracy for 18F-DCFBC PET [18]. The combination of MRI and PET/CT information might be of particular interest for planning radiotherapy of prostate cancer in the setting of personalized treatment approaches in the future [19]. In the evaluation of the dominant intraprostatic lesion, Zamboglou et al [20] found 47% agreement between multiparametric MRI and Ga-68 HBED-CC PSMA PET/CT in correlation with histopathology.…”

Section: Discussionmentioning

confidence: 96%

Usefulness of Ga-68 HBED-CC PSMA PET/CT for Tumor Staging in the Initial Diagnostic Assessment of Prostate Cancer

Schreiter¹,

Gericke²

2016

J Nucl Med Radiat Ther

View full text Add to dashboard Cite

Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer

Cited by 498 publications

References 38 publications

PSMA Ligands for PET Imaging of Prostate Cancer

PSMA Ligands for PET Imaging of Prostate Cancer

German Multicenter Study Investigating¹⁷⁷Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients

Usefulness of Ga-68 HBED-CC PSMA PET/CT for Tumor Staging in the Initial Diagnostic Assessment of Prostate Cancer

Contact Info

Product

Resources

About

Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer

Cited by 498 publications

References 38 publications

PSMA Ligands for PET Imaging of Prostate Cancer

PSMA Ligands for PET Imaging of Prostate Cancer

German Multicenter Study Investigating177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients

Usefulness of Ga-68 HBED-CC PSMA PET/CT for Tumor Staging in the Initial Diagnostic Assessment of Prostate Cancer

Contact Info

Product

Resources

About

German Multicenter Study Investigating¹⁷⁷Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients